Gain Therapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 26, 2024. This is an annual report, not a standalone fourth-quarter report. Gain is a clinical-stage biotechnology company with no product sales; its lead candidate, GT-02287, is being developed for GBA1 Parkinson’s disease.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $55,000 | $140,000 |
| Research and development expense | $11.5 million | $8.4 million |
| General and administrative expense | $10.8 million | $9.5 million |
| Operating loss | $22.3 million | $17.8 million |
| Net loss | $22.3 million | $17.6 million |
| Net loss per share | $1.71 | $1.48 |
| Cash used in operating activities | $18.9 million | $14.7 million |
Revenue was primarily collaboration-related and is not material relative to expenses. The filing reports no meaningful operating margin; the company remains loss-making and has not generated product revenue. Interest income was $0.49 million, while net foreign-exchange loss was $0.43 million, up from $0.10 million in 2022.
At year-end, cash, cash equivalents and marketable securities totaled $16.8 million, down from $22.1 million. Current assets were $17.8 million and current liabilities $4.9 million. Loans totaled approximately $0.57 million; operating lease liabilities were approximately $0.46 million. The company reported an accumulated deficit of $60.8 million. Operating cash outflow increased year over year.
Material changes and financing
- R&D expense rose $3.1 million, mainly due to external development costs and initiation of the GT-02287 Phase 1 trial. G&A rose $1.3 million, primarily from professional fees and stock-based compensation.
- Gain raised net proceeds of approximately $3.5 million through its at-the-market program and $9.2 million from a November public offering and concurrent private placement. The transactions issued shares and warrants; the ATM program was terminated in connection with the November financing.
- Shares outstanding increased from 11.9 million at December 31, 2022 to 16.2 million at December 31, 2023. The November financing included warrants exercisable at $2.75 per share and 1.76 million pre-funded warrants; those pre-funded warrants were exercised in the first quarter of 2024.
Outlook, risks and notable items
- Going concern: The company states that substantial doubt exists about its ability to continue as a going concern. Management estimates available cash will fund anticipated operating and capital requirements into the first quarter of 2025, but says funds are insufficient for at least 12 months from issuance of the financial statements. No committed external funding or credit line was reported. Further financing, cost reductions, partnerships or grants are needed; none is assured.
- Clinical outlook: The Phase 1 trial of GT-02287 began in Australia in September 2023. The multiple-ascending-dose portion began in February 2024; management anticipated completion in Q2 2024 and an audited interim report in Q3 2024. The company planned to amend the study to include 12–15 Parkinson’s patients treated for three months. These are plans and expectations, not reported outcomes.
- Management planned to begin longer-duration chronic toxicology studies in the second half of 2024. Other programs—including GM1 gangliosidosis, Krabbe disease, alpha-1 antitrypsin deficiency and oncology—remain in research or discovery stages.
- Key risks include clinical and regulatory failure, difficulty enrolling patients for rare diseases, reliance on third-party manufacturers and research organizations, dependence on licensed technology, competition, intellectual-property uncertainty, and the need for additional capital. The company also identifies foreign-exchange exposure and broad market and geopolitical uncertainty.
- The independent auditor issued an unmodified opinion on the financial statements but highlighted the going-concern uncertainty. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-controls attestation.
- Subsequent events included the CFO’s announced resignation, effective March 1, 2024, and exercise of the pre-funded warrants in Q1 2024. The filing reported no legal proceedings.
Important facts for investors to verify
- Current cash runway and financing plans, including any subsequent financing, collaboration, grant or cost-reduction actions.
- Actual Phase 1 results, safety and tolerability findings, biomarker data, and timing or approval of the planned patient cohort.
- Fully diluted share count and potential dilution from outstanding public, private, agent and equity-compensation awards.
- Whether R&D commitments—reported at $4 million with one-year contractual maturity—have changed or been fulfilled.
- Progress on the planned chronic toxicology program and on other pipeline projects, including whether any have advanced beyond discovery.